cysteine/infarction

FIELD OF INVENTION The present invention relates to methods of synthesizing S-allyl-cysteine analogues and their therapeutic composition and applications in treating myocardial infarction. BACKGROUND OF INVENTION Myocardial infarction is irreversible necrosis of heart muscle cells caused by ischemic

BACKGROUND OF THE INVENTION Cysteine proteases, such as cathepsins B, L, S, and O.sub.2, have been implicated in a number of diseases, including cancer metastasis and invasion (Clin. Exp. Metastasis 1992, 10, 145-155; Cancer Metastasis Rev. 1990, 9, 333-352), arthritis (Int. J. Biochem. 1993, 25,

BACKGROUND OF THE INVENTION Cysteine proteinases containing a highly reactive cysteine residue with a free thiol group at the active site have been known as playing an important role in certain conditions distinguished by aberrant protein turnover such as: muscular dystrophy (Am. J. Pathol. 1986,

BACKGROUND OF INVENTION Cysteine proteinases containing a highly reactive cysteine residue with a free thiol group at the active site have been known as playing important role in certain conditions distinguished by aberrant protein turnover such as: muscular dystrophy (Am. J. Pathol. 1986, 122,

BACKGROUND OF THE INVENTION Cysteine proteinases containing a highly reactive cysteine residue with a free thiol group at the active site have been known as playing an important role in certain conditions distinguished by aberrant protein turnover such as: muscular dystrophy (Am. J. Pathol. 1986,

BACKGROUND OF THE INVENTION Cysteine proteinases containing a highly reactive cysteine residue with a free thiol group at the active site have been known as playing an important role in certain conditions distinguished by aberrant protein turnover such as: muscular dystrophy (Am. J. Pathol. 1986,

BACKGROUND OF INVENTION Cysteine proteases, such as cathepsins B, H, K, L, S, and O.sub.2, containing a highly reactive cysteine residue with a free thiol group at the active site have been known as playing an important role in certain conditions distinguished by aberrant protein turnover such as:

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a novel sulfonamide derivative. More particularly, it relates to a novel sulfonamide derivative or a salt thereof which shows a strong inhibitory activity against cysteine protease such as calpain, cathepsin B,

BACKGROUND OF THE INVENTION Cysteine proteases have been viewed as lysosomal mediators of terminal protein degradation. Several newly discovered members of this enzyme class, however, are regulated proteases with limited tissue expression, which implies specific roles in cellular physiology and thus

TECHNICAL FIELD This invention relates to the treatment of respiratory, cardiac and blood disorders by delivery into the lungs of compound comprising NO. BACKGROUND OF THE INVENTION Inhaled NO is used to treat elevated pulmonary pressures and pulmonary disorders associated with hypoxemia. This

TECHNICAL FIELD This invention relates to the treatment of respiratory, cardiac and blood disorders by delivery into the lungs of compound comprising NO substitute. BACKGROUND OF THE INVENTION Inhaled NO is used to treat elevated pulmonary pressures and pulmonary disorders associated with hypoxemia.

TECHNICAL FIELD This invention relates to the assay of troponin I and troponin T and complexes of these proteins, and more specifically to the changes in conformation of these proteins in blood, serum and plasma and to the selection of antibodies to the various forms of these proteins and their use

TECHNICAL FIELD This invention relates to the assay of troponin I and troponin T and complexes of these proteins, and more specifically to the changes in conformation of these proteins in blood, serum and plasma and to the selection of antibodies to the various forms of these proteins and their use

TECHNICAL FIELD This invention relates to the assay of troponin I and troponin T and complexes of these proteins, and more specifically to the changes in conformation of these proteins in blood, serum and plasma and to the selection of antibodies to the various forms of these proteins and their use

TECHNICAL FIELD This invention relates to the assay of troponin I and troponin T and complexes of these proteins, and more specifically to the changes in conformation of these proteins in blood, serum and plasma and to the selection of antibodies to the various forms of these proteins and their use